Ładuje się......
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P(1) Receptor Modulator in Clinical Trials
[Image: see text] Clinical validation of S1P receptor modulation therapy was achieved with the approval of fingolimod (Gilenya, 1) as the first oral therapy for relapsing remitting multiple sclerosis. However, 1 causes a dose-dependent reduction in the heart rate (bradycardia), which occurs within h...
Zapisane w:
| Wydane w: | ACS Med Chem Lett |
|---|---|
| Główni autorzy: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
American Chemical
Society
2016
|
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4789672/ https://ncbi.nlm.nih.gov/pubmed/26985316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.5b00448 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|